Drawing for REMARVOL

USPTO serial 76137667

REMARVOL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
FRENCH, CURTIS W
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with REMARVOL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular conditions, epilepsy, mood disorders, pain, anxiety, cancer, auto-immune deficiency, diabetes and related conditionsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Feb 4, 2005MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 4, 2005ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 15, 2004CFITCASE FILE IN TICRS
Jul 15, 2004CFITCASE FILE IN TICRS
Apr 26, 2004DOCKASSIGNED TO EXAMINER
Mar 16, 2004EX5GSOU EXTENSION 5 GRANTED
Mar 16, 2004EXT5SOU EXTENSION 5 FILED
Mar 16, 2004EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 15, 2003EX4GSOU EXTENSION 4 GRANTED
Sep 8, 2003EXT4SOU EXTENSION 4 FILED
Sep 8, 2003EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 10, 2003EX3GSOU EXTENSION 3 GRANTED
Feb 6, 2003EXT3SOU EXTENSION 3 FILED
Feb 6, 2003EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 11, 2002EX2GSOU EXTENSION 2 GRANTED
Sep 13, 2002EXT2SOU EXTENSION 2 FILED
Sep 13, 2002MAILPAPER RECEIVED
Apr 19, 2002EX1GSOU EXTENSION 1 GRANTED
Mar 25, 2002EXT1SOU EXTENSION 1 FILED
Sep 25, 2001NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 3, 2001PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 20, 2001NPUBNOTICE OF PUBLICATION
Feb 12, 2001CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 7, 2001DOCKASSIGNED TO EXAMINER

Frequently asked questions

Related guidance